European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and the publication of practice-changing randomized trial...

Full description

Saved in:
Bibliographic Details
Published inNeuro-oncology (Charlottesville, Va.) Vol. 25; no. 1; pp. 37 - 53
Main Authors Hoang-Xuan, Khê, Deckert, Martina, Ferreri, Andrés J M, Furtner, Julia, Gallego Perez-Larraya, Jaime, Henriksson, Roger, Hottinger, Andreas F, Kasenda, Benjamin, Lefranc, Florence, Lossos, Alexander, McBain, Catherine, Preusser, Matthias, Roth, Patrick, Rudà, Roberta, Schlegel, Uwe, Soffietti, Riccardo, Soussain, Carole, Taphoorn, Martin J B, Touitou, Valérie, Weller, Michael, Bromberg, Jacoline E C
Format Journal Article
LanguageEnglish
Published England Oxford University Press 05.01.2023
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Central Nervous System - pathology
Central Nervous System Neoplasms - pathology
chemotherapy
Combined Modality Therapy
Guidelines
Humans
immunotherapy
Lymphoma - drug therapy
primary CNS lymphoma
radiotherapy
treatment
radiotherapy
treatment
chemotherapy
primary CNS lymphoma
immunotherapy
Online AccessGet full text
ISSN1522-8517
1523-5866
1523-5866
DOI10.1093/neuonc/noac196

Cover

Abstract The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and the publication of practice-changing randomized trials, the European Association of Neuro-Oncology (EANO) created a multidisciplinary task force to update the previously published evidence-based guidelines for immunocompetent adult patients with PCNSL and added a section on immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly. The main changes from the previous guideline include strengthened evidence for the consolidation with ASCT in first-line treatment, prospectively assessed chemotherapy combinations for both young and elderly patients, clarification of the role of rituximab even though the data remain inconclusive, of the role of new agents, and the incorporation of immunosuppressed patients and primary ocular lymphoma. The guideline should aid the clinicians in everyday practice and decision making and serve as a basis for future research in the field.
AbstractList The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and the publication of practice-changing randomized trials, the European Association of Neuro-Oncology (EANO) created a multidisciplinary task force to update the previously published evidence-based guidelines for immunocompetent adult patients with PCNSL and added a section on immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly. The main changes from the previous guideline include strengthened evidence for the consolidation with ASCT in first-line treatment, prospectively assessed chemotherapy combinations for both young and elderly patients, clarification of the role of rituximab even though the data remain inconclusive, of the role of new agents, and the incorporation of immunosuppressed patients and primary ocular lymphoma. The guideline should aid the clinicians in everyday practice and decision making and serve as a basis for future research in the field.
The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and the publication of practice-changing randomized trials, the European Association of Neuro-Oncology (EANO) created a multidisciplinary task force to update the previously published evidence-based guidelines for immunocompetent adult patients with PCNSL and added a section on immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly. The main changes from the previous guideline include strengthened evidence for the consolidation with ASCT in first-line treatment, prospectively assessed chemotherapy combinations for both young and elderly patients, clarification of the role of rituximab even though the data remain inconclusive, of the role of new agents, and the incorporation of immunosuppressed patients and primary ocular lymphoma. The guideline should aid the clinicians in everyday practice and decision making and serve as a basis for future research in the field.The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and the publication of practice-changing randomized trials, the European Association of Neuro-Oncology (EANO) created a multidisciplinary task force to update the previously published evidence-based guidelines for immunocompetent adult patients with PCNSL and added a section on immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly. The main changes from the previous guideline include strengthened evidence for the consolidation with ASCT in first-line treatment, prospectively assessed chemotherapy combinations for both young and elderly patients, clarification of the role of rituximab even though the data remain inconclusive, of the role of new agents, and the incorporation of immunosuppressed patients and primary ocular lymphoma. The guideline should aid the clinicians in everyday practice and decision making and serve as a basis for future research in the field.
Author Taphoorn, Martin J B
Bromberg, Jacoline E C
McBain, Catherine
Henriksson, Roger
Hottinger, Andreas F
Soussain, Carole
Weller, Michael
Rudà, Roberta
Deckert, Martina
Gallego Perez-Larraya, Jaime
Lefranc, Florence
Hoang-Xuan, Khê
Roth, Patrick
Furtner, Julia
Schlegel, Uwe
Lossos, Alexander
Soffietti, Riccardo
Ferreri, Andrés J M
Kasenda, Benjamin
Preusser, Matthias
Touitou, Valérie
Author_xml – sequence: 1
  givenname: Khê
  surname: Hoang-Xuan
  fullname: Hoang-Xuan, Khê
– sequence: 2
  givenname: Martina
  surname: Deckert
  fullname: Deckert, Martina
– sequence: 3
  givenname: Andrés J M
  surname: Ferreri
  fullname: Ferreri, Andrés J M
– sequence: 4
  givenname: Julia
  surname: Furtner
  fullname: Furtner, Julia
– sequence: 5
  givenname: Jaime
  surname: Gallego Perez-Larraya
  fullname: Gallego Perez-Larraya, Jaime
– sequence: 6
  givenname: Roger
  surname: Henriksson
  fullname: Henriksson, Roger
– sequence: 7
  givenname: Andreas F
  surname: Hottinger
  fullname: Hottinger, Andreas F
– sequence: 8
  givenname: Benjamin
  surname: Kasenda
  fullname: Kasenda, Benjamin
– sequence: 9
  givenname: Florence
  surname: Lefranc
  fullname: Lefranc, Florence
– sequence: 10
  givenname: Alexander
  surname: Lossos
  fullname: Lossos, Alexander
– sequence: 11
  givenname: Catherine
  surname: McBain
  fullname: McBain, Catherine
– sequence: 12
  givenname: Matthias
  orcidid: 0000-0003-3541-2315
  surname: Preusser
  fullname: Preusser, Matthias
– sequence: 13
  givenname: Patrick
  surname: Roth
  fullname: Roth, Patrick
– sequence: 14
  givenname: Roberta
  surname: Rudà
  fullname: Rudà, Roberta
– sequence: 15
  givenname: Uwe
  surname: Schlegel
  fullname: Schlegel, Uwe
– sequence: 16
  givenname: Riccardo
  orcidid: 0000-0002-9204-7038
  surname: Soffietti
  fullname: Soffietti, Riccardo
– sequence: 17
  givenname: Carole
  surname: Soussain
  fullname: Soussain, Carole
– sequence: 18
  givenname: Martin J B
  surname: Taphoorn
  fullname: Taphoorn, Martin J B
– sequence: 19
  givenname: Valérie
  surname: Touitou
  fullname: Touitou, Valérie
– sequence: 20
  givenname: Michael
  orcidid: 0000-0002-1748-174X
  surname: Weller
  fullname: Weller, Michael
– sequence: 21
  givenname: Jacoline E C
  surname: Bromberg
  fullname: Bromberg, Jacoline E C
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35953526$$D View this record in MEDLINE/PubMed
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-203552$$DView record from Swedish Publication Index
BookMark eNp1Us1v2yAUR1Ortc123XHimB7c2mCwuUyKsqydFCWT9nFFGD-nTDZkYHfyfz_SuFNbqSdA7_fxeL93gU6ss4DQhyy9ylJBry0Mzupr65TOBH-DzjNGaMJKzk8e7iQpWVacoYsQfqcpyRjP3qIzygSjjPBzNK4G7_agLF6E4LRRvXEWuwZvIBaSrdWudbsRz1eLzfYS7wZTQ2ssBNw4j3sPqu_A9gfG3ptO-RHr-PaqxRb8vRsCDmPoocPt2O3vXKfw_Nty8319-Q6dNqoN8H46Z-jnl9WP5W2y3t58XS7Wic5F3iclB6gpa4CVeSmKoiK0aXKRaaJIzbgqCRSpShVUtK5KpXhKCqiLvBKKUE4onaHkqBv-wn6o5NSmdMrIz-bXQjq_k0M3SJJSFoc3Q5-O-AjuoJ5-84z2vGLNndy5eylKwihlUWA-CXj3Z4DQy84EDW2rLMR5SFLEHATl-aG3j0-9_ps85hMB-RGgvQvBQyO16R8yitamlVkqD2sgj2sgpzWItKsXtEflVwj_AN93uyc
CitedBy_id crossref_primary_10_25259_SNI_431_2023
crossref_primary_10_1177_09564624241273809
crossref_primary_10_1002_cam4_70182
crossref_primary_10_7887_jcns_33_170
crossref_primary_10_1007_s00259_023_06334_w
crossref_primary_10_1093_neuonc_noae032
crossref_primary_10_1093_neuonc_noae039
crossref_primary_10_3390_cancers15235564
crossref_primary_10_3390_neuroglia5040025
crossref_primary_10_7887_jcns_32_163
crossref_primary_10_1007_s00277_023_05140_6
crossref_primary_10_1016_j_ejmp_2024_104864
crossref_primary_10_3233_XST_240016
crossref_primary_10_1007_s00401_023_02613_w
crossref_primary_10_1016_j_clineuro_2024_108551
crossref_primary_10_1016_S2352_3026_24_00104_2
crossref_primary_10_1093_neuonc_noae251
crossref_primary_10_1097_CCO_0000000000000975
crossref_primary_10_1007_s11060_024_04893_y
crossref_primary_10_1007_s11912_024_01609_3
crossref_primary_10_1016_j_wneu_2025_123740
crossref_primary_10_3389_fonc_2024_1465961
crossref_primary_10_1016_j_neurol_2023_03_012
crossref_primary_10_1093_noajnl_vdae119
crossref_primary_10_1097_CCO_0000000000000981
crossref_primary_10_1007_s00277_024_05989_1
crossref_primary_10_1007_s00415_023_12143_w
crossref_primary_10_3389_fonc_2024_1463505
crossref_primary_10_1093_jjco_hyae116
crossref_primary_10_1186_s13000_025_01626_1
crossref_primary_10_3390_cancers17060917
crossref_primary_10_3390_cancers16050860
crossref_primary_10_3892_ol_2024_14859
crossref_primary_10_1111_bjh_18758
crossref_primary_10_1055_s_0042_1759712
crossref_primary_10_1182_blood_2023022020
crossref_primary_10_1007_s00432_023_05338_1
crossref_primary_10_1007_s44178_024_00086_9
crossref_primary_10_1212_WNL_0000000000209748
crossref_primary_10_1002_phar_2889
crossref_primary_10_1186_s42466_023_00234_y
crossref_primary_10_1016_j_bas_2025_104187
crossref_primary_10_1016_j_neurol_2023_08_021
crossref_primary_10_1093_noajnl_vdad012
crossref_primary_10_1002_ccr3_8409
crossref_primary_10_3390_biology13020099
crossref_primary_10_1016_j_bas_2023_101791
crossref_primary_10_1039_D3AN00670K
crossref_primary_10_3389_fneur_2024_1431614
crossref_primary_10_2217_fon_2023_0529
crossref_primary_10_1111_bjh_19238
crossref_primary_10_1007_s11060_022_04200_7
crossref_primary_10_1016_j_clml_2023_10_012
crossref_primary_10_1001_jama_2023_0023
crossref_primary_10_1007_s00701_024_06138_3
crossref_primary_10_1016_j_ejca_2024_115198
crossref_primary_10_1093_neuonc_noae270
crossref_primary_10_1007_s11060_023_04504_2
crossref_primary_10_1159_000540051
crossref_primary_10_25259_SNI_65_2024
crossref_primary_10_3390_cancers15041341
crossref_primary_10_1093_neuonc_noac246
crossref_primary_10_1093_neuonc_noad015
crossref_primary_10_1097_CCO_0000000000001097
crossref_primary_10_3390_medsci11010014
crossref_primary_10_1080_10428194_2024_2342560
crossref_primary_10_12968_hmed_2024_0243
crossref_primary_10_1002_hon_3198
crossref_primary_10_3390_cancers15215266
crossref_primary_10_3390_curroncol31110491
crossref_primary_10_1093_neuonc_noae029
crossref_primary_10_1038_s41598_025_88351_3
crossref_primary_10_1093_noajnl_vdae093
crossref_primary_10_1016_j_asjsur_2023_12_206
Cites_doi 10.1200/JCO.2012.46.9957
10.1093/annonc/mdl070
10.1182/bloodadvances.2020004106
10.1212/WNL.54.8.1707
10.1097/CCO.0000000000000776
10.1200/JCO.2015.64.9897
10.3324/haematol.2012.076075
10.1016/j.ijrobp.2020.02.466
10.1212/WNL.0b013e31820f2d94
10.1093/neuros/nyy096
10.1002/cncr.11035
10.1097/IAE.0b013e31820a6743
10.1007/s11060-010-0497-x
10.1016/j.ejca.2004.03.008
10.3109/10428194.2011.584004
10.1007/s11060-019-03257-1
10.1002/1097-0142(19890515)63:10<1918::AID-CNCR2820631008>3.0.CO;2-D
10.3171/jns.1999.91.2.0221
10.1200/JCO.2006.06.6910
10.1111/ajt.12211
10.1097/00002030-200308150-00007
10.1002/hon.2037
10.1200/JCO.2003.03.036
10.1093/neuonc/not032
10.3324/haematol.2011.060434
10.1016/S1470-2045(18)30356-5
10.3324/haematol.11771
10.1002/cncr.26709
10.1007/s11060-010-0457-5
10.1001/jamaoncol.2021.1074
10.1212/WNL.0b013e318297eeba
10.1182/blood-2018-09-875732
10.1182/blood.2021014738
10.1182/bloodadvances.2020002064
10.1038/s41598-020-80724-0
10.1093/neuonc/nos207
10.1093/neuonc/nou259.2
10.1200/JCO.2003.11.036
10.1212/WNL.0000000000012515
10.1200/JCO.1998.16.3.864
10.3109/10428194.2011.633250
10.1002/ajh.23551
10.1099/vir.0.80440-0
10.1038/bmt.2017.23
10.1038/leu.2017.170
10.1158/1078-0432.CCR-04-0159
10.1200/JCO.1996.14.2.556
10.1093/neuonc/nos159
10.1093/annonc/mdf080
10.1186/s12883-021-02227-3
10.1200/JCO.2011.39.9642
10.1212/WNL.0000000000010949
10.1007/s11060-019-03208-w
10.1093/annonc/mdp529
10.1212/WNL.62.4.544
10.1093/annonc/mdq712
10.1182/blood-2002-06-1636
10.1200/JCO.1992.10.4.635
10.1007/s00432-017-2423-5
10.1182/bloodadvances.2017014845
10.3389/fonc.2021.649789
10.1200/JCO.2021.39.15_suppl.7506
10.1007/s11060-014-1370-0
10.1007/s11060-011-0649-7
10.1007/s12185-013-1403-z
10.1007/s11060-016-2358-8
10.1093/neuonc/noq011
10.1586/14737140.2013.851007
10.1182/blood.V86.8.2922.2922
10.1200/JCO.2018.78.8687
10.1007/s11060-014-1411-8
10.1093/annonc/mdz032
10.1002/ajh.26199
10.1136/bjo.2007.127928
10.1038/s41375-022-01582-5
10.1001/jamaophthalmol.2014.4755
10.1016/S2352-3026(15)00074-5
10.1111/j.1468-1331.2004.00867.x
10.1200/JCO.2008.19.3789
10.1093/annonc/mdn628
10.1016/j.ijrobp.2006.03.061
10.1200/JCO.2020.38.15_suppl.2500
10.1002/cncr.20300
10.1212/WNL.0000000000004265
10.1016/0360-3016(95)00207-F
10.1002/cncr.23077
10.1016/j.clml.2020.07.008
10.3324/haematol.2014.108472
10.1167/tvst.1.3.1
10.2174/157016206777709429
10.1093/neuonc/now033
10.1093/neuonc/nox187
10.1007/s10143-018-0946-0
10.1215/15228517-2008-067
10.1093/neuonc/nor186
10.1016/0360-3016(92)90538-S
10.1002/1097-0142(197410)34:4<1293::AID-CNCR2820340441>3.0.CO;2-P
10.1212/WNL.0000000000000593
10.1016/S1470-2045(18)30747-2
10.1016/S0140-6736(09)61416-1
10.1007/s11060-009-0032-0
10.1158/2159-8290.CD-17-0613
10.3109/10428194.2012.698736
10.1093/annonc/mdl464
10.1038/nrc3702
10.3324/haematol.2020.247536
10.1111/j.1365-2141.2010.08328.x
10.1212/01.WNL.0000034256.20173.EA
10.1097/00002030-200111090-00007
10.1093/neuonc/noab021
10.1016/j.ccell.2017.04.012
10.1016/S1470-2045(10)70229-1
10.1007/s11060-011-0608-3
10.1093/neurosurgery/46.1.51
10.1007/s11060-008-9712-4
10.1111/j.1365-2141.2004.05028.x
10.1038/s41409-022-01648-z
10.1093/annonc/mdv076
10.1002/hon.2666
10.1002/ana.10102
10.1212/WNL.58.10.1513
10.1136/bjo.73.5.342
10.1007/s11060-012-0891-7
10.1200/JCO.2002.11.013
10.1007/s12185-010-0703-9
10.1007/s11255-012-0146-8
10.1002/hon.944
10.1200/JCO.1998.16.3.859
10.1034/j.1600-0609.2003.00045.x
10.1200/JCO.2003.04.056
10.1097/CCO.0b013e32834b6adc
10.1038/leu.2017.128
10.1086/499956
10.1038/sj.eye.6702437
10.1182/blood.2021012932
10.1002/cncr.25363
10.1200/JCO.2003.03.108
10.1038/leu.2016.334
10.1001/archneur.62.10.1595
10.1200/JCO.2005.01.161
10.1309/N82CTQ1J0XEVEFQB
10.1080/10428194.2020.1742903
10.1212/01.wnl.0000327672.04729.8c
10.1212/WNL.0000000000000314
10.1212/01.wnl.0000276986.19602.c1
10.1212/01.WNL.0000109673.75316.D8
10.1182/blood.2020006048
10.1093/neuonc/noaa145
10.1016/j.clml.2018.11.018
10.1634/theoncologist.2011-0210
10.1093/neuonc/now155
10.1002/cncr.23670
10.1111/ajt.14465
10.1016/j.ijrobp.2010.01.066
10.1007/s11060-015-1994-8
10.1200/JCO.2003.05.024
10.3324/haematol.2017.185843
10.1007/s11060-008-9761-8
10.1093/annonc/mdm340
10.2147/OTT.S192379
10.1182/blood.2019003073
10.1016/S2352-3026(17)30174-6
10.1093/annonc/mdi075
10.1200/JCO.2001.19.3.742
10.1016/S2352-3026(16)00036-3
10.3171/jns.2000.92.2.0261
10.1212/WNL.0b013e318266fcb2
10.1002/cncr.24834
10.1016/j.ejca.2019.05.024
10.1200/JCO.2013.50.4910
10.1093/annonc/mdr553
10.1182/blood-2018-02-835496
10.1200/JCO.2020.38.15_suppl.2501
10.1200/JCO.2007.13.5533
10.3109/10428194.2014.916800
10.1182/bloodadvances.2020002270
10.1007/s00277-018-3564-6
10.1002/ana.21824
10.1023/A:1016077907952
10.1097/00042560-199808010-00008
10.1016/S1470-2045(15)00076-5
10.1038/s41571-021-00479-z
10.1200/JCO.18.00306
10.1007/s11060-007-9397-0
10.1182/blood-2017-01-764209
ContentType Journal Article
Copyright The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2022
Copyright_xml – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
– notice: The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTPV
AOWAS
D93
DOI 10.1093/neuonc/noac196
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
SwePub
SwePub Articles
SWEPUB Umeå universitet
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1523-5866
EndPage 53
ExternalDocumentID oai_DiVA_org_umu_203552
PMC9825335
35953526
10_1093_neuonc_noac196
Genre Journal Article
GroupedDBID ---
.2P
.I3
.XZ
.ZR
0R~
123
18M
2WC
36B
4.4
48X
53G
5VS
5WD
70D
AABZA
AACZT
AAJKP
AAMDB
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAVAP
AAYXX
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABNHQ
ABNKS
ABPQP
ABPTD
ABQLI
ABQNK
ABVGC
ABWST
ABXVV
ABZBJ
ACGFO
ACGFS
ACUFI
ACUTO
ACYHN
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFXAL
AGINJ
AGKEF
AGORE
AGQXC
AGSYK
AGUTN
AHGBF
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
AOIJS
APIBT
APWMN
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CDBKE
CITATION
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EMB
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HYE
HZ~
IOX
J21
JXSIZ
KOP
KQ8
KSI
KSN
MHKGH
N9A
NGC
NOMLY
NOYVH
O9-
OAUYM
OAWHX
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
P6G
PAFKI
PEELM
Q1.
Q5Y
RD5
ROX
RPM
RUSNO
RW1
RXO
SV3
TEORI
TJX
TR2
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
~91
ADJQC
ADRIX
AFXEN
CGR
CUY
CVF
ECM
EIF
NPM
RHF
7X8
5PM
KBUDW
1TH
29N
AAJQQ
AAUQX
ADTPV
AOWAS
D93
EJD
NU-
O0~
UDS
ID FETCH-LOGICAL-c494t-86eed35fe5848977b23ff491c2a2d56a82e70a0aeb3db8aa6027ed74b9a236233
ISSN 1522-8517
1523-5866
IngestDate Thu Aug 21 06:46:07 EDT 2025
Thu Aug 21 18:40:58 EDT 2025
Sat Sep 27 21:37:04 EDT 2025
Wed Feb 19 02:22:33 EST 2025
Thu Apr 24 23:03:38 EDT 2025
Tue Jul 01 03:40:03 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords radiotherapy
treatment
chemotherapy
primary CNS lymphoma
immunotherapy
Language English
License https://academic.oup.com/pages/standard-publication-reuse-rights
The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c494t-86eed35fe5848977b23ff491c2a2d56a82e70a0aeb3db8aa6027ed74b9a236233
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-1748-174X
0000-0003-3541-2315
0000-0002-9204-7038
OpenAccessLink http://hdl.handle.net/1887/3503817
PMID 35953526
PQID 2702193643
PQPubID 23479
PageCount 17
ParticipantIDs swepub_primary_oai_DiVA_org_umu_203552
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9825335
proquest_miscellaneous_2702193643
pubmed_primary_35953526
crossref_citationtrail_10_1093_neuonc_noac196
crossref_primary_10_1093_neuonc_noac196
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-01-05
PublicationDateYYYYMMDD 2023-01-05
PublicationDate_xml – month: 01
  year: 2023
  text: 2023-01-05
  day: 05
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: US
PublicationTitle Neuro-oncology (Charlottesville, Va.)
PublicationTitleAlternate Neuro Oncol
PublicationYear 2023
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Korfel (2023010802380884500_CIT0140) 2016; 34
Soussain (2023010802380884500_CIT0175) 2001; 19
Kiefer (2023010802380884500_CIT0113) 2012; 23
Hoang-Xuan (2023010802380884500_CIT0143) 2020
Schorb (2023010802380884500_CIT0163) 2020; 4
van der Meulen (2023010802380884500_CIT0005) 2017; 31
Lai (2023010802380884500_CIT0100) 2002; 59
Ferreri (2023010802380884500_CIT0130) 2020; 4
Rae (2023010802380884500_CIT0021) 2019; 84
Schmitt (2023010802380884500_CIT0028) 2019; 37
Rubenstein (2023010802380884500_CIT0075) 2003; 101
Schenone (2023010802380884500_CIT0115) 2022; 57
Narita (2023010802380884500_CIT0136) 2021; 23
Malaise (2023010802380884500_CIT0179) 2021; 33
Citterio (2023010802380884500_CIT0101) 2013; 13
Soussain (2023010802380884500_CIT0052) 2019; 117
Hoang-Xuan (2023010802380884500_CIT0017) 2015; 16
Nelson (2023010802380884500_CIT0089) 1992; 23
DeAngelis (2023010802380884500_CIT0098) 2002; 20
Doolittle (2023010802380884500_CIT0031) 2013; 81
Berenbom (2023010802380884500_CIT0167) 2007; 21
Tao (2023010802380884500_CIT0117) 2021; 11
Nayak (2023010802380884500_CIT0051) 2013; 54
Dabaja (2023010802380884500_CIT0102) 2020; 107
Mohile (2023010802380884500_CIT0164) 2018; 36
del Rio (2023010802380884500_CIT0120) 2011; 105
Rubenstein (2023010802380884500_CIT0054) 2018; 2
Deckert (2023010802380884500_CIT0001) 2021
Correa (2023010802380884500_CIT0109) 2019; 144
Grimm (2023010802380884500_CIT0177) 2008; 71
Rubenstein (2023010802380884500_CIT0036) 2013; 31
Blay (2023010802380884500_CIT0105) 1998; 16
Hiraga (2023010802380884500_CIT0070) 1999; 91
Rajagopal (2023010802380884500_CIT0176) 2011; 31
Khan (2023010802380884500_CIT0087) 2002; 58
Batchelor (2023010802380884500_CIT0072) 2003; 21
Schultz (2023010802380884500_CIT0148) 1996; 14
Welch (2023010802380884500_CIT0043) 2015; 56
Chamberlain (2023010802380884500_CIT0079) 2010; 12
Langner-Lemercier (2023010802380884500_CIT0118) 2016; 18
Schaadt (2023010802380884500_CIT0180) 2005; 86
Tun (2023010802380884500_CIT0139) 2018; 132
Cloney (2023010802380884500_CIT0068) 2017; 132
van der Meulen (2023010802380884500_CIT0157) 2021; 106
Yu (2023010802380884500_CIT0022) 2021; 11
Seidel (2023010802380884500_CIT0074) 2020; 95
Kasenda (2023010802380884500_CIT0162) 2015; 26
Pels (2023010802380884500_CIT0085) 2009; 91
Jahr (2023010802380884500_CIT0069) 2018; 41
Ferreri (2023010802380884500_CIT0009) 2016; 3
Reni (2023010802380884500_CIT0122) 2004; 40
Cavaliere (2023010802380884500_CIT0063) 2010; 116
Houillier (2023010802380884500_CIT0138) 2021; 97
Jan (2023010802380884500_CIT0137) 2021; 18
Soussain (2023010802380884500_CIT0041) 2008; 26
Kasenda (2023010802380884500_CIT0121) 2017; 31
Mahale (2023010802380884500_CIT0186) 2018; 18
Fritsch (2023010802380884500_CIT0080) 2011; 22
Chamberlain (2023010802380884500_CIT0128) 2016; 126
O’Neill (2023010802380884500_CIT0147) 1995; 33
Ferreri (2023010802380884500_CIT0086) 2002; 58
Roth (2023010802380884500_CIT0149) 2012; 79
Hoang-Xuan (2023010802380884500_CIT0025) 2003; 21
van der Meulen (2023010802380884500_CIT0108) 2021; 23
O’Neill (2023010802380884500_CIT0004) 2013; 88
Ferreri (2023010802380884500_CIT0010) 2017; 4
Siddiqi (2023010802380884500_CIT0144) 2021; 5
Hottinger (2023010802380884500_CIT0044) 2007; 69
Nguyen (2023010802380884500_CIT0045) 2005; 23
Hoffmann (2023010802380884500_CIT0058) 2001; 15
Abrey (2023010802380884500_CIT0110) 2003; 21
Bossolasco (2023010802380884500_CIT0184) 2006; 42
Iwamoto (2023010802380884500_CIT0076) 2007; 110
van der Meulen (2023010802380884500_CIT0107) 2018; 19
Harder (2023010802380884500_CIT0030) 2004; 62
Chamberlain (2023010802380884500_CIT0125) 2014; 118
Ferreri (2023010802380884500_CIT0023) 2009;; 374
Pentsova (2023010802380884500_CIT0050) 2014; 117
Castellano-Sanchez (2023010802380884500_CIT0185) 2004; 121
Omuro (2023010802380884500_CIT0032) 2005; 62
Abrey (2023010802380884500_CIT0106) 1998; 16
Lionakis (2023010802380884500_CIT0134) 2017; 31
Gupta (2023010802380884500_CIT0061) 2017; 19
Bessell (2023010802380884500_CIT0159) 2011; 104
Hashida (2023010802380884500_CIT0169) 2012; 1
Collignon (2023010802380884500_CIT0129) 2019; 98
Baron (2023010802380884500_CIT0174) 2020; 135
McAllister (2023010802380884500_CIT0073) 2000; 46
Welch (2023010802380884500_CIT0156) 2012; 14
Kurzwelly (2023010802380884500_CIT0155) 2010; 97
Plotkin (2023010802380884500_CIT0049) 2004; 10
Alcantara (2023010802380884500_CIT0056) 2022; 139
Fischer (2023010802380884500_CIT0123) 2006; 17
Illerhaus (2023010802380884500_CIT0112) 2008; 93
Ungur (2023010802380884500_CIT0119) 2015; 8
Mappa (2023010802380884500_CIT0046) 2013; 31
Lurain (2023010802380884500_CIT0062) 2020; 136
Provencher (2023010802380884500_CIT0131) 2011; 29
Ekenel (2023010802380884500_CIT0094) 2008; 113
Omuro (2023010802380884500_CIT0095) 2011; 104
Correa (2023010802380884500_CIT0104) 2007; 18
Birsen (2023010802380884500_CIT0037) 2018; 103
Jahnke (2023010802380884500_CIT0173) 2009; 93
González-Aguilar (2023010802380884500_CIT0183) 2011; 23
Grommes (2023010802380884500_CIT0135) 2017; 7
Houillier (2023010802380884500_CIT0013) 2022
Herrlinger (2023010802380884500_CIT0099) 2017; 143
Bromberg (2023010802380884500_CIT0007) 2019; 20
Fritsch (2023010802380884500_CIT0024) 2017; 31
Alimohamed (2023010802380884500_CIT0111) 2012; 53
Correa (2023010802380884500_CIT0161) 2012; 14
Ferreri (2023010802380884500_CIT0097) 2011; 80
Batchelor (2023010802380884500_CIT0016) 2021; 39
Poortmans (2023010802380884500_CIT0092) 2003; 21
Schorb (2023010802380884500_CIT0116) 2017; 52
Omuro (2023010802380884500_CIT0150) 2007; 85
Schorb (2023010802380884500_CIT0114) 2013; 98
Thiel (2023010802380884500_CIT0033) 2010; 11
Choi (2023010802380884500_CIT0047) 2013; 98
Ferreri (2023010802380884500_CIT0012) 2022; 36
Raizer (2023010802380884500_CIT0124) 2012; 118
Henry (2023010802380884500_CIT0065) 1974; 34
Correa (2023010802380884500_CIT0029) 2004; 62
Ferreri (2023010802380884500_CIT0132) 2014; 82
Schuurmans (2023010802380884500_CIT0152) 2010; 151
Arellano-Rodrigo (2023010802380884500_CIT0127) 2003; 70
Weller (2023010802380884500_CIT0020) 2012; 14
Valavoor (2023010802380884500_CIT0188) 2013; 45
Ghesquieres (2023010802380884500_CIT0093) 2010; 21
Taoka (2023010802380884500_CIT0153) 2010; 92
Holdhoff (2023010802380884500_CIT0083) 2014; 83
Batchelor (2023010802380884500_CIT0170) 2003; 9
Gregory (2023010802380884500_CIT0082) 2013; 15
Grimm (2023010802380884500_CIT0039) 2007; 18
Ghesquieres (2023010802380884500_CIT0055) 2019; 30
Hormigo (2023010802380884500_CIT0166) 2004; 126
Illerhaus (2023010802380884500_CIT0145) 2009; 20
Soussain (2023010802380884500_CIT0042) 2012; 97
Blay (2023010802380884500_CIT0091) 1995; 86
Pulczynski (2023010802380884500_CIT0026) 2015; 100
Ammassari (2023010802380884500_CIT0003) 1998; 18
Omuro (2023010802380884500_CIT0014) 2020; 38
Shibamoto (2023010802380884500_CIT0103) 2003; 97
Brainin (2023010802380884500_CIT0018) 2004; 11
Bataille (2023010802380884500_CIT0066) 2000; 92
Angelov (2023010802380884500_CIT0027) 2009; 27
Sierra Del Rio (2023010802380884500_CIT0088) 2012; 106
Ferreri (2023010802380884500_CIT0178) 2002; 13
Omuro (2023010802380884500_CIT0008) 2015; 2
Skiest (2023010802380884500_CIT0059) 2003; 17
Kallam (2023010802380884500_CIT0190) 2020; 20
Kazuhiko (2023010802380884500_CIT0015) 2020; 38
Wu (2023010802380884500_CIT0067) 2021; 21
Gerard (2023010802380884500_CIT0096) 2011; 52
Chan (2023010802380884500_CIT0165) 2011; 16
Houillier (2023010802380884500_CIT0011) 2019; 37
Alnahhas (2023010802380884500_CIT0034) 2019; 19
Herrlinger (2023010802380884500_CIT0126) 2000; 54
Strauchen (2023010802380884500_CIT0172) 1989; 63
Nayak (2023010802380884500_CIT0141) 2017; 129
Juergens (2023010802380884500_CIT0160) 2010; 67
Batchelor (2023010802380884500_CIT0077) 2011; 76
Morris (2023010802380884500_CIT0078) 2013; 31
Gavrilovic (2023010802380884500_CIT0090) 2006; 24
Krishnamurthy (2023010802380884500_CIT0189) 2014; 16
Herrlinger (2023010802380884500_CIT0071) 2002; 51
Riemens (2023010802380884500_CIT0040) 2015; 133
Travi (2023010802380884500_CIT0182) 2012; 30
Grommes (2023010802380884500_CIT0053) 2019; 133
Siegel (2023010802380884500_CIT0171) 1989; 73
Mendez (2023010802380884500_CIT0006) 2018; 20
Pels (2023010802380884500_CIT0084) 2003; 21
Laack (2023010802380884500_CIT0146) 2006; 65
Diamond (2023010802380884500_CIT0002) 2006; 4
Moulignier (2023010802380884500_CIT0060) 2017; 89
Evens (2023010802380884500_CIT0064) 2013; 13
Jahnke (2023010802380884500_CIT0158) 2005; 16
Ney (2023010802380884500_CIT0151) 2010; 116
Scordo (2023010802380884500_CIT0035) 2021; 7
Lam (2023010802380884500_CIT0038) 2021; 96
Frenkel (2023010802380884500_CIT0168) 2008; 92
DeAngelis (2023010802380884500_CIT0019) 1992; 10
Birnbaum (2023010802380884500_CIT0081) 2012; 109
Zhu (2023010802380884500_CIT0154) 2009; 11
Kaulen (2023010802380884500_CIT0187) 2019; 144
Holdhoff (2023010802380884500_CIT0048) 2020; 13
Hendriks (2023010802380884500_CIT0133) 2014; 14
Newell (2023010802380884500_CIT0181) 2004; 100
Graber (2023010802380884500_CIT0142) 2020; 61
Frigault (2023010802380884500_CIT0057) 2022; 139
References_xml – volume: 31
  start-page: 3061
  year: 2013
  ident: 2023010802380884500_CIT0036
  article-title: Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.46.9957
– volume: 17
  start-page: 1141
  year: 2006
  ident: 2023010802380884500_CIT0123
  article-title: Prospective trial on topotecan salvage therapy in primary CNS lymphoma
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdl070
– volume: 5
  start-page: 4059
  year: 2021
  ident: 2023010802380884500_CIT0144
  article-title: CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2020004106
– volume: 54
  start-page: 1707
  year: 2000
  ident: 2023010802380884500_CIT0126
  article-title: PCV salvage chemotherapy for recurrent primary CNS lymphoma
  publication-title: Neurology
  doi: 10.1212/WNL.54.8.1707
– volume: 33
  start-page: 420
  year: 2021
  ident: 2023010802380884500_CIT0179
  article-title: Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up
  publication-title: Curr Opin Oncol
  doi: 10.1097/CCO.0000000000000776
– volume: 34
  start-page: 1757
  year: 2016
  ident: 2023010802380884500_CIT0140
  article-title: Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.64.9897
– volume: 98
  start-page: 765
  year: 2013
  ident: 2023010802380884500_CIT0114
  article-title: Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation
  publication-title: Haematologica
  doi: 10.3324/haematol.2012.076075
– volume: 107
  start-page: 398
  year: 2020
  ident: 2023010802380884500_CIT0102
  article-title: The challenges of applying radiation in primary central nervous system lymphoma
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2020.02.466
– volume: 76
  start-page: 929
  year: 2011
  ident: 2023010802380884500_CIT0077
  article-title: Rituximab monotherapy for patients with recurrent primary CNS lymphoma
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e31820f2d94
– volume: 84
  start-page: 935
  year: 2019
  ident: 2023010802380884500_CIT0021
  article-title: Craniotomy and survival for primary central nervous system lymphoma
  publication-title: Neurosurgery
  doi: 10.1093/neuros/nyy096
– volume: 97
  start-page: 128
  year: 2003
  ident: 2023010802380884500_CIT0103
  article-title: Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation
  publication-title: Cancer
  doi: 10.1002/cncr.11035
– volume: 31
  start-page: 435
  year: 2011
  ident: 2023010802380884500_CIT0176
  article-title: Diagnostic testing and treatment choices in primary vitreoretinal lymphoma
  publication-title: Retina
  doi: 10.1097/IAE.0b013e31820a6743
– volume: 104
  start-page: 323
  year: 2011
  ident: 2023010802380884500_CIT0095
  article-title: Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?
  publication-title: J Neurooncol
  doi: 10.1007/s11060-010-0497-x
– volume: 40
  start-page: 1682
  year: 2004
  ident: 2023010802380884500_CIT0122
  article-title: Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2004.03.008
– volume: 52
  start-page: 1882
  year: 2011
  ident: 2023010802380884500_CIT0096
  article-title: High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2011.584004
– volume: 144
  start-page: 553
  year: 2019
  ident: 2023010802380884500_CIT0109
  article-title: Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation
  publication-title: J Neurooncol
  doi: 10.1007/s11060-019-03257-1
– volume: 63
  start-page: 1918
  year: 1989
  ident: 2023010802380884500_CIT0172
  article-title: Chemotherapy in the management of intraocular lymphoma
  publication-title: Cancer
  doi: 10.1002/1097-0142(19890515)63:10<1918::AID-CNCR2820631008>3.0.CO;2-D
– volume: 91
  start-page: 221
  year: 1999
  ident: 2023010802380884500_CIT0070
  article-title: Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas
  publication-title: J Neurosurg
  doi: 10.3171/jns.1999.91.2.0221
– volume: 24
  start-page: 4570
  year: 2006
  ident: 2023010802380884500_CIT0090
  article-title: Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2006.06.6910
– volume: 13
  start-page: 1512
  year: 2013
  ident: 2023010802380884500_CIT0064
  article-title: Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era
  publication-title: Am J Transplant
  doi: 10.1111/ajt.12211
– volume: 17
  start-page: 1787
  year: 2003
  ident: 2023010802380884500_CIT0059
  article-title: Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma
  publication-title: AIDS
  doi: 10.1097/00002030-200308150-00007
– volume: 31
  start-page: 143
  year: 2013
  ident: 2023010802380884500_CIT0046
  article-title: Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy
  publication-title: Hematol Oncol
  doi: 10.1002/hon.2037
– volume: 21
  start-page: 1044
  year: 2003
  ident: 2023010802380884500_CIT0072
  article-title: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2003.03.036
– volume: 15
  start-page: 1068
  year: 2013
  ident: 2023010802380884500_CIT0082
  article-title: Rituximab is associated with improved survival for aggressive B cell CNS lymphoma
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/not032
– volume: 97
  start-page: 1751
  year: 2012
  ident: 2023010802380884500_CIT0042
  article-title: Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases
  publication-title: Haematologica
  doi: 10.3324/haematol.2011.060434
– volume: 19
  start-page: e407
  year: 2018
  ident: 2023010802380884500_CIT0107
  article-title: Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30356-5
– volume: 93
  start-page: 147
  year: 2008
  ident: 2023010802380884500_CIT0112
  article-title: High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system
  publication-title: Haematologica
  doi: 10.3324/haematol.11771
– volume: 118
  start-page: 3743
  year: 2012
  ident: 2023010802380884500_CIT0124
  article-title: Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma
  publication-title: Cancer
  doi: 10.1002/cncr.26709
– volume: 104
  start-page: 191
  year: 2011
  ident: 2023010802380884500_CIT0159
  article-title: Increasing age at diagnosis and worsening renal function in patients with primary central nervous system lymphoma
  publication-title: J Neurooncol
  doi: 10.1007/s11060-010-0457-5
– volume: 7
  start-page: 993
  year: 2021
  ident: 2023010802380884500_CIT0035
  article-title: Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2021.1074
– volume: 81
  start-page: 84
  year: 2013
  ident: 2023010802380884500_CIT0031
  article-title: Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e318297eeba
– volume: 133
  start-page: 436
  year: 2019
  ident: 2023010802380884500_CIT0053
  article-title: Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma
  publication-title: Blood
  doi: 10.1182/blood-2018-09-875732
– volume: 139
  start-page: 2306
  year: 2022
  ident: 2023010802380884500_CIT0057
  article-title: Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial
  publication-title: Blood
  doi: 10.1182/blood.2021014738
– volume: 4
  start-page: 3378
  year: 2020
  ident: 2023010802380884500_CIT0163
  article-title: High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2020002064
– volume: 11
  start-page: 2125
  year: 2021
  ident: 2023010802380884500_CIT0022
  article-title: High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials
  publication-title: Sci Rep
  doi: 10.1038/s41598-020-80724-0
– volume: 14
  start-page: 1304
  year: 2012
  ident: 2023010802380884500_CIT0156
  article-title: Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/nos207
– volume: 16
  start-page: v119
  year: 2014
  ident: 2023010802380884500_CIT0189
  article-title: Temozolomide in primary central nervous system post-transplant lymphoproliferative disorder (CNS-PTLD): a case series
  publication-title: Neuro-Oncology
  doi: 10.1093/neuonc/nou259.2
– volume: 21
  start-page: 2726
  year: 2003
  ident: 2023010802380884500_CIT0025
  article-title: Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2003.11.036
– volume: 97
  start-page: 628
  year: 2021
  ident: 2023010802380884500_CIT0138
  article-title: Rituximab-lenalidomide-ibrutinib combination for relapsed/refractory primary CNS lymphoma: a case series of the LOC network
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000012515
– volume: 16
  start-page: 864
  year: 1998
  ident: 2023010802380884500_CIT0105
  article-title: High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.1998.16.3.864
– volume: 53
  start-page: 862
  year: 2012
  ident: 2023010802380884500_CIT0111
  article-title: Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2011.633250
– volume: 88
  start-page: 997
  year: 2013
  ident: 2023010802380884500_CIT0004
  article-title: The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma
  publication-title: Am J Hematol
  doi: 10.1002/ajh.23551
– volume: 86
  start-page: 551
  year: 2005
  ident: 2023010802380884500_CIT0180
  article-title: Epstein-Barr virus latent membrane protein 2A mimics B-cell receptor-dependent virus reactivation
  publication-title: J Gen Virol
  doi: 10.1099/vir.0.80440-0
– volume: 52
  start-page: 1113
  year: 2017
  ident: 2023010802380884500_CIT0116
  article-title: High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study
  publication-title: Bone Marrow Transpl.
  doi: 10.1038/bmt.2017.23
– volume: 31
  start-page: 2623
  year: 2017
  ident: 2023010802380884500_CIT0121
  article-title: High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group
  publication-title: Leukemia
  doi: 10.1038/leu.2017.170
– volume: 10
  start-page: 5643
  year: 2004
  ident: 2023010802380884500_CIT0049
  article-title: Treatment of relapsed central nervous system lymphoma with high-dose methotrexate
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0159
– volume: 14
  start-page: 556
  year: 1996
  ident: 2023010802380884500_CIT0148
  article-title: Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.1996.14.2.556
– volume: 14
  start-page: 1481
  year: 2012
  ident: 2023010802380884500_CIT0020
  article-title: Surgery for primary CNS lymphoma? Challenging a paradigm
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/nos159
– volume: 13
  start-page: 531
  year: 2002
  ident: 2023010802380884500_CIT0178
  article-title: Relevance of intraocular involvement in the management of primary central nervous system lymphomas
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdf080
– volume: 21
  start-page: 190
  year: 2021
  ident: 2023010802380884500_CIT0067
  article-title: The role of surgical resection in primary central nervous system lymphoma: a single-center retrospective analysis of 70 patients
  publication-title: BMC Neurol
  doi: 10.1186/s12883-021-02227-3
– volume: 30
  start-page: e119
  year: 2012
  ident: 2023010802380884500_CIT0182
  article-title: Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.39.9642
– volume: 95
  start-page: e3138
  year: 2020
  ident: 2023010802380884500_CIT0074
  article-title: Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000010949
– volume: 144
  start-page: 107
  year: 2019
  ident: 2023010802380884500_CIT0187
  article-title: Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma
  publication-title: J Neurooncol
  doi: 10.1007/s11060-019-03208-w
– start-page: 351
  volume-title: Primary diffuse large B cell lymphoma of the CNS, World Health Organization Classification of Tumours of the Central Nervous System 2021
  year: 2021
  ident: 2023010802380884500_CIT0001
– volume: 21
  start-page: 842
  year: 2010
  ident: 2023010802380884500_CIT0093
  article-title: Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA)
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdp529
– volume: 62
  start-page: 544
  year: 2004
  ident: 2023010802380884500_CIT0030
  article-title: Cognitive status and quality of life after treatment for primary CNS lymphoma
  publication-title: Neurology
  doi: 10.1212/WNL.62.4.544
– volume: 22
  start-page: 2080
  year: 2011
  ident: 2023010802380884500_CIT0080
  article-title: Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdq712
– volume: 101
  start-page: 466
  year: 2003
  ident: 2023010802380884500_CIT0075
  article-title: Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment
  publication-title: Blood
  doi: 10.1182/blood-2002-06-1636
– volume: 10
  start-page: 635
  year: 1992
  ident: 2023010802380884500_CIT0019
  article-title: Combined modality therapy for primary CNS lymphoma
  publication-title: J. Clin. Oncol
  doi: 10.1200/JCO.1992.10.4.635
– volume: 143
  start-page: 1815
  year: 2017
  ident: 2023010802380884500_CIT0099
  article-title: Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-017-2423-5
– volume: 2
  start-page: 1595
  year: 2018
  ident: 2023010802380884500_CIT0054
  article-title: Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2017014845
– volume: 11
  start-page: 649789
  year: 2021
  ident: 2023010802380884500_CIT0117
  article-title: Relapsed primary central nervous system lymphoma: current advances
  publication-title: Front Oncol
  doi: 10.3389/fonc.2021.649789
– volume: 39
  start-page: 7506
  year: 2021
  ident: 2023010802380884500_CIT0016
  article-title: Leonard J.P., Rubenstein J.L.: Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: results of induction therapy in Alliance 51101
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2021.39.15_suppl.7506
– volume: 117
  start-page: 161
  year: 2014
  ident: 2023010802380884500_CIT0050
  article-title: Methotrexate re-challenge for recurrent primary central nervous system lymphoma
  publication-title: J Neurooncol
  doi: 10.1007/s11060-014-1370-0
– volume: 106
  start-page: 143
  year: 2012
  ident: 2023010802380884500_CIT0088
  article-title: Prophylactic intrathecal chemotherapy in primary CNS lymphoma
  publication-title: J Neurooncol
  doi: 10.1007/s11060-011-0649-7
– volume: 98
  start-page: 346
  year: 2013
  ident: 2023010802380884500_CIT0047
  article-title: Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation
  publication-title: Int J Hematol
  doi: 10.1007/s12185-013-1403-z
– volume: 132
  start-page: 189
  year: 2017
  ident: 2023010802380884500_CIT0068
  article-title: The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis
  publication-title: J Neurooncol
  doi: 10.1007/s11060-016-2358-8
– volume: 12
  start-page: 736
  year: 2010
  ident: 2023010802380884500_CIT0079
  article-title: High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/noq011
– volume: 13
  start-page: 1327
  year: 2013
  ident: 2023010802380884500_CIT0101
  article-title: Current uses of radiation therapy in patients with primary CNS lymphoma
  publication-title: Expert Rev Anticancer Ther
  doi: 10.1586/14737140.2013.851007
– volume: 86
  start-page: 2922
  year: 1995
  ident: 2023010802380884500_CIT0091
  article-title: The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin’s lymphoma of patients with no known cause of immunosuppression
  publication-title: Blood
  doi: 10.1182/blood.V86.8.2922.2922
– volume: 36
  start-page: 2326
  year: 2018
  ident: 2023010802380884500_CIT0164
  article-title: Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.78.8687
– volume: 118
  start-page: 155
  year: 2014
  ident: 2023010802380884500_CIT0125
  article-title: Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series
  publication-title: J Neurooncol
  doi: 10.1007/s11060-014-1411-8
– volume: 30
  start-page: 621
  year: 2019
  ident: 2023010802380884500_CIT0055
  article-title: Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective “proof of concept” phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdz032
– volume: 96
  start-page: 823
  year: 2021
  ident: 2023010802380884500_CIT0038
  article-title: Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study
  publication-title: Am J Hematol
  doi: 10.1002/ajh.26199
– volume: 92
  start-page: 383
  year: 2008
  ident: 2023010802380884500_CIT0168
  article-title: Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience
  publication-title: Br J Ophthalmol
  doi: 10.1136/bjo.2007.127928
– volume: 36
  start-page: 1870
  year: 2022
  ident: 2023010802380884500_CIT0012
  article-title: Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
  publication-title: Leukemia
  doi: 10.1038/s41375-022-01582-5
– volume: 133
  start-page: 191
  year: 2015
  ident: 2023010802380884500_CIT0040
  article-title: Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study
  publication-title: JAMA Ophthalmol
  doi: 10.1001/jamaophthalmol.2014.4755
– volume: 9
  start-page: 711
  year: 2003
  ident: 2023010802380884500_CIT0170
  article-title: High-dose methotrexate for intraocular lymphoma
  publication-title: Clin Cancer Res
– volume: 2
  start-page: e251
  year: 2015
  ident: 2023010802380884500_CIT0008
  article-title: Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial
  publication-title: Lancet Haematol
  doi: 10.1016/S2352-3026(15)00074-5
– volume: 11
  start-page: 577
  year: 2004
  ident: 2023010802380884500_CIT0018
  article-title: Guidance for the preparation of neurological management guidelines by EFNS scientific task forces--revised recommendations 2004
  publication-title: Eur. J. Neurol
  doi: 10.1111/j.1468-1331.2004.00867.x
– volume: 27
  start-page: 3503
  year: 2009
  ident: 2023010802380884500_CIT0027
  article-title: Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.19.3789
– volume: 20
  start-page: 319
  year: 2009
  ident: 2023010802380884500_CIT0145
  article-title: High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdn628
– volume: 65
  start-page: 1429
  year: 2006
  ident: 2023010802380884500_CIT0146
  article-title: Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2006.03.061
– volume: 38
  start-page: 2500
  year: 2020
  ident: 2023010802380884500_CIT0015
  article-title: Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma: JCOG1114C
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2020.38.15_suppl.2500
– volume: 100
  start-page: 2627
  year: 2004
  ident: 2023010802380884500_CIT0181
  article-title: Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients
  publication-title: Cancer.
  doi: 10.1002/cncr.20300
– volume: 89
  start-page: 796
  year: 2017
  ident: 2023010802380884500_CIT0060
  article-title: Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000004265
– volume: 33
  start-page: 663
  year: 1995
  ident: 2023010802380884500_CIT0147
  article-title: Primary central nervous system non-Hodgkin’s lymphoma: survival advantages with combined initial therapy?
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/0360-3016(95)00207-F
– volume: 110
  start-page: 2528
  year: 2007
  ident: 2023010802380884500_CIT0076
  article-title: Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma
  publication-title: Cancer
  doi: 10.1002/cncr.23077
– volume: 20
  start-page: e930
  year: 2020
  ident: 2023010802380884500_CIT0190
  article-title: Central Nervous System Post-transplant lymphoproliferative disorder: response to ibrutinib
  publication-title: Clin Lymphoma Myeloma Leuk
  doi: 10.1016/j.clml.2020.07.008
– volume: 100
  start-page: 534
  year: 2015
  ident: 2023010802380884500_CIT0026
  article-title: Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group
  publication-title: Haematologica
  doi: 10.3324/haematol.2014.108472
– volume: 1
  start-page: 1
  year: 2012
  ident: 2023010802380884500_CIT0169
  article-title: Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma
  publication-title: Transl Vis Sci Technol
  doi: 10.1167/tvst.1.3.1
– volume: 4
  start-page: 375
  year: 2006
  ident: 2023010802380884500_CIT0002
  article-title: Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin’s lymphoma
  publication-title: Curr HIV Res
  doi: 10.2174/157016206777709429
– volume: 18
  start-page: 1297
  year: 2016
  ident: 2023010802380884500_CIT0118
  article-title: Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/now033
– volume: 20
  start-page: 687
  year: 2018
  ident: 2023010802380884500_CIT0006
  article-title: The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/nox187
– volume: 41
  start-page: 1037
  year: 2018
  ident: 2023010802380884500_CIT0069
  article-title: The role of surgery in intracranial PCNSL
  publication-title: Neurosurg Rev
  doi: 10.1007/s10143-018-0946-0
– volume: 11
  start-page: 211
  year: 2009
  ident: 2023010802380884500_CIT0154
  article-title: High-dose methotrexate for elderly patients with primary CNS lymphoma
  publication-title: Neuro Oncol
  doi: 10.1215/15228517-2008-067
– volume: 14
  start-page: 101
  year: 2012
  ident: 2023010802380884500_CIT0161
  article-title: Cognitive functions in primary CNS lymphoma after single or combined modality regimens
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/nor186
– volume: 23
  start-page: 9
  year: 1992
  ident: 2023010802380884500_CIT0089
  article-title: Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315
  publication-title: Int J Radiat. Oncol Biol Phys.
  doi: 10.1016/0360-3016(92)90538-S
– volume: 34
  start-page: 1293
  year: 1974
  ident: 2023010802380884500_CIT0065
  article-title: Primary malignant lymphomas of the central nervous system
  publication-title: Cancer
  doi: 10.1002/1097-0142(197410)34:4<1293::AID-CNCR2820340441>3.0.CO;2-P
– volume: 83
  start-page: 235
  year: 2014
  ident: 2023010802380884500_CIT0083
  article-title: High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000000593
– volume: 20
  start-page: 216
  year: 2019
  ident: 2023010802380884500_CIT0007
  article-title: Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30747-2
– volume: 374
  start-page: 1512
  year: 2009;
  ident: 2023010802380884500_CIT0023
  article-title: High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)61416-1
– volume: 97
  start-page: 389
  year: 2010
  ident: 2023010802380884500_CIT0155
  article-title: Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status
  publication-title: J Neurooncol
  doi: 10.1007/s11060-009-0032-0
– volume: 7
  start-page: 1018
  year: 2017
  ident: 2023010802380884500_CIT0135
  article-title: Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-17-0613
– volume: 54
  start-page: 58
  year: 2013
  ident: 2023010802380884500_CIT0051
  article-title: Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2012.698736
– volume: 18
  start-page: 1145
  year: 2007
  ident: 2023010802380884500_CIT0104
  article-title: Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines
  publication-title: Ann Oncol.
  doi: 10.1093/annonc/mdl464
– volume: 14
  start-page: 219
  year: 2014
  ident: 2023010802380884500_CIT0133
  article-title: Targeting Bruton’s tyrosine kinase in B cell malignancies
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3702
– volume: 106
  start-page: 597
  year: 2021
  ident: 2023010802380884500_CIT0157
  article-title: Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands
  publication-title: Haematologica
  doi: 10.3324/haematol.2020.247536
– volume: 151
  start-page: 179
  year: 2010
  ident: 2023010802380884500_CIT0152
  article-title: Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis
  publication-title: Br J of Haematol
  doi: 10.1111/j.1365-2141.2010.08328.x
– volume: 59
  start-page: 1557
  year: 2002
  ident: 2023010802380884500_CIT0100
  article-title: Primary CNS lymphoma: a whole-brain disease?
  publication-title: Neurology
  doi: 10.1212/01.WNL.0000034256.20173.EA
– volume: 15
  start-page: 2119
  year: 2001
  ident: 2023010802380884500_CIT0058
  article-title: Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery
  publication-title: AIDS
  doi: 10.1097/00002030-200111090-00007
– volume: 23
  start-page: 1315
  year: 2021
  ident: 2023010802380884500_CIT0108
  article-title: Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/noab021
– volume: 31
  start-page: 833
  year: 2017
  ident: 2023010802380884500_CIT0134
  article-title: Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.04.012
– volume: 11
  start-page: 1036
  year: 2010
  ident: 2023010802380884500_CIT0033
  article-title: High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70229-1
– volume: 105
  start-page: 409
  year: 2011
  ident: 2023010802380884500_CIT0120
  article-title: Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma
  publication-title: J Neurooncol
  doi: 10.1007/s11060-011-0608-3
– volume: 46
  start-page: 51
  year: 2000
  ident: 2023010802380884500_CIT0073
  article-title: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma
  publication-title: Neurosurgery
  doi: 10.1093/neurosurgery/46.1.51
– volume: 91
  start-page: 299
  year: 2009
  ident: 2023010802380884500_CIT0085
  article-title: Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study
  publication-title: J Neurooncol
  doi: 10.1007/s11060-008-9712-4
– volume: 126
  start-page: 202
  year: 2004
  ident: 2023010802380884500_CIT0166
  article-title: Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2004.05028.x
– volume: 57
  start-page: 966
  year: 2022
  ident: 2023010802380884500_CIT0115
  article-title: Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network
  publication-title: Bone Marrow Transpl.
  doi: 10.1038/s41409-022-01648-z
– volume: 26
  start-page: 1305
  year: 2015
  ident: 2023010802380884500_CIT0162
  article-title: First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdv076
– volume: 37
  start-page: 548
  year: 2019
  ident: 2023010802380884500_CIT0028
  article-title: Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis
  publication-title: Hematol Oncol
  doi: 10.1002/hon.2666
– volume: 51
  start-page: 247
  year: 2002
  ident: 2023010802380884500_CIT0071
  article-title: German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma
  publication-title: Ann Neurol
  doi: 10.1002/ana.10102
– volume: 58
  start-page: 1513
  year: 2002
  ident: 2023010802380884500_CIT0086
  article-title: A multicenter study of treatment of primary CNS lymphoma
  publication-title: Neurology
  doi: 10.1212/WNL.58.10.1513
– volume: 73
  start-page: 342
  year: 1989
  ident: 2023010802380884500_CIT0171
  article-title: Ten-year experience with primary ocular “reticulum cell sarcoma” (large cell non-Hodgkin’s lymphoma)
  publication-title: Br J Ophthalmol
  doi: 10.1136/bjo.73.5.342
– volume: 109
  start-page: 285
  year: 2012
  ident: 2023010802380884500_CIT0081
  article-title: Rituximab significantly improves complete response rate in patients with primary CNS lymphoma
  publication-title: J Neurooncol
  doi: 10.1007/s11060-012-0891-7
– volume: 20
  start-page: 4643
  year: 2002
  ident: 2023010802380884500_CIT0098
  article-title: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2002.11.013
– volume: 92
  start-page: 617
  year: 2010
  ident: 2023010802380884500_CIT0153
  article-title: A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma
  publication-title: Int J Hematol
  doi: 10.1007/s12185-010-0703-9
– volume: 45
  start-page: 1219
  year: 2013
  ident: 2023010802380884500_CIT0188
  article-title: Conservative management of post-transplant central nervous system lymphoma
  publication-title: Int Urol Nephrol
  doi: 10.1007/s11255-012-0146-8
– volume: 29
  start-page: 10
  year: 2011
  ident: 2023010802380884500_CIT0131
  article-title: Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series
  publication-title: Hematol Oncol
  doi: 10.1002/hon.944
– volume: 16
  start-page: 859
  year: 1998
  ident: 2023010802380884500_CIT0106
  article-title: Long-term survival in primary CNS lymphoma
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.1998.16.3.859
– volume: 70
  start-page: 219
  year: 2003
  ident: 2023010802380884500_CIT0127
  article-title: Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma
  publication-title: Eur J. Haematol
  doi: 10.1034/j.1600-0609.2003.00045.x
– volume: 21
  start-page: 4489
  year: 2003
  ident: 2023010802380884500_CIT0084
  article-title: Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy
  publication-title: J. Clin. Oncol
  doi: 10.1200/JCO.2003.04.056
– volume: 23
  start-page: 648
  year: 2011
  ident: 2023010802380884500_CIT0183
  article-title: The management of primary central nervous system lymphoma related to AIDS in the HAART era
  publication-title: Curr Opin Oncol
  doi: 10.1097/CCO.0b013e32834b6adc
– volume: 31
  start-page: 1822
  year: 2017
  ident: 2023010802380884500_CIT0005
  article-title: Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015
  publication-title: Leukemia
  doi: 10.1038/leu.2017.128
– volume: 42
  start-page: e21
  year: 2006
  ident: 2023010802380884500_CIT0184
  article-title: Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma
  publication-title: Clin Infect Dis
  doi: 10.1086/499956
– volume: 21
  start-page: 1198
  year: 2007
  ident: 2023010802380884500_CIT0167
  article-title: Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy
  publication-title: Eye (Lond)
  doi: 10.1038/sj.eye.6702437
– volume: 139
  start-page: 792
  year: 2022
  ident: 2023010802380884500_CIT0056
  article-title: CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network
  publication-title: Blood
  doi: 10.1182/blood.2021012932
– start-page: 15
  year: 2020
  ident: 2023010802380884500_CIT0143
  article-title: First results of the Acsé pembrolizumab phase II in the primary CNS lymphoma (PCNSL) Cohort
  publication-title: ASH
– volume: 116
  start-page: 4605
  year: 2010
  ident: 2023010802380884500_CIT0151
  article-title: Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience
  publication-title: Cancer
  doi: 10.1002/cncr.25363
– volume: 21
  start-page: 4483
  year: 2003
  ident: 2023010802380884500_CIT0092
  article-title: High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2003.03.108
– volume: 31
  start-page: 846
  year: 2017
  ident: 2023010802380884500_CIT0024
  article-title: High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)
  publication-title: Leukemia
  doi: 10.1038/leu.2016.334
– volume: 62
  start-page: 1595
  year: 2005
  ident: 2023010802380884500_CIT0032
  article-title: Delayed neurotoxicity in primary central nervous system lymphoma
  publication-title: Arch Neurol
  doi: 10.1001/archneur.62.10.1595
– volume: 23
  start-page: 1507
  year: 2005
  ident: 2023010802380884500_CIT0045
  article-title: Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2005.01.161
– volume: 121
  start-page: 246
  year: 2004
  ident: 2023010802380884500_CIT0185
  article-title: Primary central nervous system posttransplant lymphoproliferative disorders
  publication-title: Am J Clin Pathol
  doi: 10.1309/N82CTQ1J0XEVEFQB
– volume: 61
  start-page: 1766
  year: 2020
  ident: 2023010802380884500_CIT0142
  article-title: Pembrolizumab immunotherapy for relapsed CNS lymphoma
  publication-title: Leuk Lymphoma
  doi: 10.1080/10428194.2020.1742903
– volume: 71
  start-page: 1355
  year: 2008
  ident: 2023010802380884500_CIT0177
  article-title: Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000327672.04729.8c
– volume: 82
  start-page: 1370
  year: 2014
  ident: 2023010802380884500_CIT0132
  article-title: MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000000314
– volume: 69
  start-page: 1178
  year: 2007
  ident: 2023010802380884500_CIT0044
  article-title: Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000276986.19602.c1
– volume: 62
  start-page: 548
  year: 2004
  ident: 2023010802380884500_CIT0029
  article-title: Cognitive functions in survivors of primary central nervous system lymphoma
  publication-title: Neurology
  doi: 10.1212/01.WNL.0000109673.75316.D8
– volume: 136
  start-page: 2229
  year: 2020
  ident: 2023010802380884500_CIT0062
  article-title: Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate
  publication-title: Blood
  doi: 10.1182/blood.2020006048
– volume: 23
  start-page: 122
  year: 2021
  ident: 2023010802380884500_CIT0136
  article-title: Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/noaa145
– start-page: CO2200491
  year: 2022
  ident: 2023010802380884500_CIT0013
  article-title: Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: long-term results of the randomized phase II PRECIS study
  publication-title: J Clin Oncol
– volume: 19
  start-page: e129
  year: 2019
  ident: 2023010802380884500_CIT0034
  article-title: Autologous stem-cell transplantation for primary central nervous system lymphoma: systematic review and meta-analysis
  publication-title: Clin Lymphoma Myeloma Leuk
  doi: 10.1016/j.clml.2018.11.018
– volume: 16
  start-page: 1589
  year: 2011
  ident: 2023010802380884500_CIT0165
  article-title: Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2011-0210
– volume: 19
  start-page: 99
  year: 2017
  ident: 2023010802380884500_CIT0061
  article-title: Long-term survival in AIDS-related primary central nervous system lymphoma
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/now155
– volume: 113
  start-page: 1025
  year: 2008
  ident: 2023010802380884500_CIT0094
  article-title: Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy
  publication-title: Cancer
  doi: 10.1002/cncr.23670
– volume: 18
  start-page: 453
  year: 2018
  ident: 2023010802380884500_CIT0186
  article-title: Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients
  publication-title: Am J Transpl
  doi: 10.1111/ajt.14465
– volume: 80
  start-page: 169
  year: 2011
  ident: 2023010802380884500_CIT0097
  article-title: Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2010.01.066
– volume: 126
  start-page: 545
  year: 2016
  ident: 2023010802380884500_CIT0128
  article-title: High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma
  publication-title: J Neurooncol
  doi: 10.1007/s11060-015-1994-8
– volume: 21
  start-page: 4151
  year: 2003
  ident: 2023010802380884500_CIT0110
  article-title: Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2003.05.024
– volume: 8
  start-page: 2771
  year: 2015
  ident: 2023010802380884500_CIT0119
  article-title: ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases
  publication-title: Onco Targets Ther
– volume: 103
  start-page: e296
  year: 2018
  ident: 2023010802380884500_CIT0037
  article-title: Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients
  publication-title: Haematologica
  doi: 10.3324/haematol.2017.185843
– volume: 93
  start-page: 213
  year: 2009
  ident: 2023010802380884500_CIT0173
  article-title: Ifosfamide or trofosfamide in patients with intraocular lymphoma
  publication-title: J Neurooncol
  doi: 10.1007/s11060-008-9761-8
– volume: 18
  start-page: 1851
  year: 2007
  ident: 2023010802380884500_CIT0039
  article-title: Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdm340
– volume: 13
  start-page: 8323
  year: 2020
  ident: 2023010802380884500_CIT0048
  article-title: Systemic approach to recurrent primary CNS lymphoma: perspective on current and emerging treatment strategies
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S192379
– volume: 135
  start-page: 1811
  year: 2020
  ident: 2023010802380884500_CIT0174
  article-title: Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma
  publication-title: Blood
  doi: 10.1182/blood.2019003073
– volume: 4
  start-page: e510
  year: 2017
  ident: 2023010802380884500_CIT0010
  article-title: Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
  publication-title: Lancet Haematol
  doi: 10.1016/S2352-3026(17)30174-6
– volume: 16
  start-page: 445
  year: 2005
  ident: 2023010802380884500_CIT0158
  article-title: High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdi075
– volume: 19
  start-page: 742
  year: 2001
  ident: 2023010802380884500_CIT0175
  article-title: Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2001.19.3.742
– volume: 3
  start-page: e217
  year: 2016
  ident: 2023010802380884500_CIT0009
  article-title: Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
  publication-title: Lancet Haematol
  doi: 10.1016/S2352-3026(16)00036-3
– volume: 92
  start-page: 261
  year: 2000
  ident: 2023010802380884500_CIT0066
  article-title: Primary intracerebral malignant lymphoma: report of 248 cases
  publication-title: J Neurosurg
  doi: 10.3171/jns.2000.92.2.0261
– volume: 79
  start-page: 890
  year: 2012
  ident: 2023010802380884500_CIT0149
  article-title: Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e318266fcb2
– volume: 116
  start-page: 863
  year: 2010
  ident: 2023010802380884500_CIT0063
  article-title: Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report
  publication-title: Cancer
  doi: 10.1002/cncr.24834
– volume: 117
  start-page: 121
  year: 2019
  ident: 2023010802380884500_CIT0052
  article-title: Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II “proof-of-concept” iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2019.05.024
– volume: 31
  start-page: 3971
  year: 2013
  ident: 2023010802380884500_CIT0078
  article-title: Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2013.50.4910
– volume: 23
  start-page: 1809
  year: 2012
  ident: 2023010802380884500_CIT0113
  article-title: Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdr553
– volume: 132
  start-page: 2240
  year: 2018
  ident: 2023010802380884500_CIT0139
  article-title: Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma
  publication-title: Blood
  doi: 10.1182/blood-2018-02-835496
– volume: 38
  start-page: 2501
  year: 2020
  ident: 2023010802380884500_CIT0014
  article-title: Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL)
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2020.38.15_suppl.2501
– volume: 26
  start-page: 2512
  year: 2008
  ident: 2023010802380884500_CIT0041
  article-title: Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.13.5533
– volume: 56
  start-page: 361
  year: 2015
  ident: 2023010802380884500_CIT0043
  article-title: Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2014.916800
– volume: 4
  start-page: 3648
  year: 2020
  ident: 2023010802380884500_CIT0130
  article-title: Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2020002270
– volume: 98
  start-page: 915
  year: 2019
  ident: 2023010802380884500_CIT0129
  article-title: (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study
  publication-title: Ann Hematol
  doi: 10.1007/s00277-018-3564-6
– volume: 67
  start-page: 182
  year: 2010
  ident: 2023010802380884500_CIT0160
  article-title: Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma
  publication-title: Ann Neurol
  doi: 10.1002/ana.21824
– volume: 58
  start-page: 175
  year: 2002
  ident: 2023010802380884500_CIT0087
  article-title: Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
  publication-title: J Neurooncol
  doi: 10.1023/A:1016077907952
– volume: 18
  start-page: 365
  year: 1998
  ident: 2023010802380884500_CIT0003
  article-title: Changing disease patterns in focal brain lesion-causing disorders in AIDS
  publication-title: J Acquir Immune Defic Syndr Hum Retrovirol
  doi: 10.1097/00042560-199808010-00008
– volume: 16
  start-page: e322
  year: 2015
  ident: 2023010802380884500_CIT0017
  article-title: Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(15)00076-5
– volume: 18
  start-page: 401
  year: 2021
  ident: 2023010802380884500_CIT0137
  article-title: Cancer therapies based on targeted protein degradation—lessons learned with lenalidomide
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-021-00479-z
– volume: 37
  start-page: 823
  year: 2019
  ident: 2023010802380884500_CIT0011
  article-title: Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.18.00306
– volume: 85
  start-page: 207
  year: 2007
  ident: 2023010802380884500_CIT0150
  article-title: Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly
  publication-title: J Neurooncol.
  doi: 10.1007/s11060-007-9397-0
– volume: 129
  start-page: 3071
  year: 2017
  ident: 2023010802380884500_CIT0141
  article-title: PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
  publication-title: Blood
  doi: 10.1182/blood-2017-01-764209
SSID ssj0021561
Score 2.6152103
Snippet The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and...
SourceID swepub
pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 37
SubjectTerms Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Central Nervous System - pathology
Central Nervous System Neoplasms - pathology
chemotherapy
Combined Modality Therapy
Guidelines
Humans
immunotherapy
Lymphoma - drug therapy
primary CNS lymphoma
radiotherapy
treatment
Title European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)
URI https://www.ncbi.nlm.nih.gov/pubmed/35953526
https://www.proquest.com/docview/2702193643
https://pubmed.ncbi.nlm.nih.gov/PMC9825335
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-203552
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFBVZB2MvY99N94EGY2sJbl3Zjp3H0CZkbZoMloy8CcmW047WhtQedL9nP3T3WrJjkwy6vRij2LKje6Kce3XvESEffSZdGTNlqSByUVQ7siTzwVVhMDNGQjqq2L3hYtIdzd2zhbdotX7XspbyTB6Gv7bWlfyPVaEN7IpVsv9g2apTaIBzsC8cwcJwvJeNq1B6bZCLEAAqbljTJNQCS0AiB_3JFAMAyxxlrTDVXecXVmnmmPhshCdMvmYngWkEE2S12HPn-g4Mn94I7O7ryeTbuAwi_CgFoPChae2hxVJ-mgGZ_YkVh0VKrTisxR5GqUiW1iLXQdjzy2LVvoLUqapXFGVmn28T_F6ZEnlMyNSL_beds3Vod5ivMlPKgxXgoh7cYE4R3PDq8zG0eUHXqGVvaTOTOPM2wKpnZC0ps_FHoUW0EpXDsOBJKsLj3hZN7smUD-fjMZ8NFrMH5CHzgaEh9f5yXrn14AFrVV7zWpU0qHOk-z8yvTepz4Y_s5mW2xCvLQjP7Cl5YjwV2tewe0ZaKnlOHl2YXIwX5K5EH62hj6YxbaKP7iP2DugaeRSQRyvk4R0GedS8EjXIoxp5tEQe3S9wd_CSzIeD2cnIMht5WKHbczMr6AITc7xYAdsNwOGQzIljt3ccMsEirysCpnxb2EJJJ5KBEF2b-SryXdkTDAiW47wiO0maqF1CXSRUdugwCbzKduJAhFEsAhlJ1w-ARLSJVY4xD43KPW62cs11toXDtU24sUmbfK6uN1_2r1d-KE3GYQrGdTWRKBgMjiWd4AcBt2-T19qEVV9Y945bULSJ3zBudQHKuzc_Sa4uC5n3XsDAF_Pa5JOGQeOW06vvfZ6uljy_yTmzwWtge_d4wTfk8fpn9pbsZKtcvQNWncn3Baj_AHMR1QA
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=European+Association+of+Neuro-Oncology+%28EANO%29+guidelines+for+treatment+of+primary+central+nervous+system+lymphoma+%28PCNSL%29&rft.jtitle=Neuro-oncology+%28Charlottesville%2C+Va.%29&rft.au=Hoang-Xuan%2C+Kh%C3%AA&rft.au=Deckert%2C+Martina&rft.au=Ferreri%2C+Andr%C3%A9s+J+M&rft.au=Furtner%2C+Julia&rft.date=2023-01-05&rft.issn=1523-5866&rft.eissn=1523-5866&rft.volume=25&rft.issue=1&rft.spage=37&rft_id=info:doi/10.1093%2Fneuonc%2Fnoac196&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-8517&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-8517&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-8517&client=summon